OverviewSuggest Edit

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, the company has created a library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. The company seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
TypePublic
Founded1998
HQNewtown, PA, US
Websiteonconova.com

Latest Updates

Employees (est.) (Dec 2019)17(-32%)
Revenue (FY, 2020)$231 K(-89%)
Share Price (Jun 2021)$7.1(-1%)
Cybersecurity ratingAMore

Key People/Management at Onconova Therapeutics

Steven M. Fruchtman

Steven M. Fruchtman

President, CEO & Director
Mark Guerin

Mark Guerin

Chief Financial Officer
Viren Mehta

Viren Mehta

Director
Jerome E. Groopman

Jerome E. Groopman

Director
Matthew Parris

Matthew Parris

Vice President, Clinical Operations
Avi Oler

Avi Oler

Senior Vice President, Corporate Development & General Counsel
Show more

Onconova Therapeutics Office Locations

Onconova Therapeutics has offices in Newtown, Boston and Pennington
Newtown, PA, US (HQ)
375 Pheasant Run
Boston, MA, US
1 Federal St
Pennington, NJ, US
73 NJ-31
Show all (3)

Onconova Therapeutics Financials and Metrics

Onconova Therapeutics Revenue

Onconova Therapeutics's revenue was reported to be $231 k in FY, 2020
USD

Revenue (Q1, 2021)

56.0k

Net income (Q1, 2021)

(4.7m)

EBIT (Q1, 2021)

(4.1m)

Market capitalization (11-Jun-2021)

1.7b

Closing stock price (11-Jun-2021)

7.1

Cash (31-Mar-2021)

48.0m
Onconova Therapeutics's current market capitalization is $1.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.8m800.0k11.5m5.5m787.0k1.2m2.2m231.0k

General and administrative expense

16.8m15.1m9.5m9.2m7.4m7.6m8.3m8.3m

R&D expense

50.2m49.4m25.9m20.1m19.1m16.9m15.5m16.9m

Operating expense total

67.0m64.5m35.4m29.2m26.5m24.5m23.9m25.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

60.0m43.6m19.8m21.4m4.0m17.0m22.7m19.0m

Accounts Receivable

1.5m141.8m59.0k35.0k98.0k37.0k

Prepaid Expenses

4.4m3.2m1.8m820.0k760.0k650.0k722.0k

Current Assets

104.4m46.9m23.2m23.1m4.9m17.8m23.5m19.8m
USDQ2, 2013

Financial Leverage

-0.3 x
Show all financial metrics

Onconova Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Onconova Therapeutics Online and Social Media Presence

Embed Graph

Onconova Therapeutics News and Updates

Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium

NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will part…

Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital

NEWTOWN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO …

Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chi…

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved…

Thinking about buying stock in Onconova Therapeutics, New Oriental Education, Seelos Therapeutics, Acasti Pharma, or CBS Corp?

NEW YORK, May 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, EDU, SEEL, ACST, and VIAC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split o…
Show more

Onconova Therapeutics Blogs

Matthew Parris

Matthew Parris Paul.alfano@na… Wed, 01/20/2021 - 09:37 Matthew Parris Vice President, Clinical Operations Mr. Parris joined Onconova Therapeutics in August 2018 as Senior Director, Clinical Operations, and is responsible for overseeing and managing the Clinical O…

Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 Content Import Mon, 11/23/2020 - 08:00 Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 Nov 23, 2020 …

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Content Import Thu, 11/12/2020 - 16:05 Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Nov 12, 2020 This release is…

Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12 NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021 NEWTOWN, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat

Onconova Therapeutics Announces Participation at Upcoming Virtual Events

Onconova Therapeutics Announces Participation at Upcoming Virtual Events Content Import Wed, 09/09/2020 - 08:01 Onconova Therapeutics Announces Participation at Upcoming Virtual Events Sep 09, 2020 This release is a backfill from a News Wire …
Show more

Onconova Therapeutics Frequently Asked Questions

  • When was Onconova Therapeutics founded?

    Onconova Therapeutics was founded in 1998.

  • Who are Onconova Therapeutics key executives?

    Onconova Therapeutics's key executives are Steven M. Fruchtman, Mark Guerin and Viren Mehta.

  • How many employees does Onconova Therapeutics have?

    Onconova Therapeutics has 17 employees.

  • What is Onconova Therapeutics revenue?

    Latest Onconova Therapeutics annual revenue is $231 k.

  • What is Onconova Therapeutics revenue per employee?

    Latest Onconova Therapeutics revenue per employee is $13.6 k.

  • Who are Onconova Therapeutics competitors?

    Competitors of Onconova Therapeutics include Moleculin Biotech, SQZ Biotech and Jiangsu Hansoh Pharmaceutical Group.

  • Where is Onconova Therapeutics headquarters?

    Onconova Therapeutics headquarters is located at 375 Pheasant Run, Newtown.

  • Where are Onconova Therapeutics offices?

    Onconova Therapeutics has offices in Newtown, Boston and Pennington.

  • How many offices does Onconova Therapeutics have?

    Onconova Therapeutics has 3 offices.